Q1 2017 EPS Estimates for Cynosure, Inc. Decreased by Analyst (CYNO)

Cynosure, Inc. (NASDAQ:CYNO) – Analysts at Griffin Securities reduced their Q1 2017 earnings per share (EPS) estimates for shares of Cynosure in a research report issued to clients and investors on Wednesday. Griffin Securities analyst Z. Ajzenman now anticipates that the firm will earn $0.26 per share for the quarter, down from their prior forecast of $0.28. Griffin Securities also issued estimates for Cynosure’s Q2 2017 earnings at $0.44 EPS, Q4 2017 earnings at $0.58 EPS, FY2017 earnings at $1.70 EPS, Q1 2018 earnings at $0.34 EPS, Q3 2018 earnings at $0.50 EPS, Q4 2018 earnings at $0.67 EPS and FY2018 earnings at $2.01 EPS.

Several other research analysts also recently issued reports on the stock. Aegis reissued a “buy” rating and set a $60.00 price objective on shares of Cynosure in a research report on Tuesday, January 24th. Northland Securities set a $60.00 price objective on shares of Cynosure and gave the stock a “buy” rating in a research report on Monday, January 23rd. Zacks Investment Research downgraded shares of Cynosure from a “hold” rating to a “sell” rating in a research report on Monday, January 9th. TheStreet raised shares of Cynosure from a “hold” rating to a “buy” rating in a research report on Wednesday, January 4th. Finally, Northcoast Research downgraded shares of Cynosure from a “buy” rating to a “sell” rating and set a $40.00 price objective on the stock. in a research report on Friday, January 6th. Two investment analysts have rated the stock with a sell rating and seven have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $57.88.

Earnings History and Estimates for Cynosure (NASDAQ:CYNO)

TRADEMARK VIOLATION NOTICE: “Q1 2017 EPS Estimates for Cynosure, Inc. Decreased by Analyst (CYNO)” was originally reported by sleekmoney and is owned by of sleekmoney. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright and trademark law. The legal version of this news story can be viewed at http://sleekmoney.com/q1-2017-eps-estimates-for-cynosure-inc-decreased-by-analyst-cyno/1655479.html.

Cynosure (NASDAQ:CYNO) opened at 55.05 on Friday. Cynosure has a 52-week low of $34.47 and a 52-week high of $55.94. The firm has a market cap of $1.30 billion, a P/E ratio of 84.69 and a beta of 1.65. The company’s 50 day moving average is $47.51 and its 200 day moving average is $48.44.

Cynosure (NASDAQ:CYNO) last released its quarterly earnings results on Tuesday, February 7th. The company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.03. Cynosure had a net margin of 3.56% and a return on equity of 6.86%. The firm earned $122.10 million during the quarter, compared to the consensus estimate of $119.97 million. During the same quarter in the prior year, the firm earned $0.42 EPS. The company’s revenue for the quarter was up 19.2% on a year-over-year basis.

In related news, VP Douglas J. Delaney sold 7,875 shares of the firm’s stock in a transaction dated Tuesday, November 22nd. The shares were sold at an average price of $45.00, for a total value of $354,375.00. Following the completion of the sale, the vice president now owns 5,833 shares in the company, valued at $262,485. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman Michael R. Davin sold 16,284 shares of the firm’s stock in a transaction dated Tuesday, November 22nd. The shares were sold at an average price of $45.00, for a total transaction of $732,780.00. Following the completion of the sale, the chairman now owns 4,222 shares of the company’s stock, valued at approximately $189,990. The disclosure for this sale can be found here. 2.90% of the stock is owned by company insiders.

TRADEMARK VIOLATION NOTICE: “Q1 2017 EPS Estimates for Cynosure, Inc. Decreased by Analyst (CYNO)” was originally reported by sleekmoney and is owned by of sleekmoney. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright and trademark law. The legal version of this news story can be viewed at http://sleekmoney.com/q1-2017-eps-estimates-for-cynosure-inc-decreased-by-analyst-cyno/1655479.html.

Several hedge funds have recently made changes to their positions in CYNO. BlackRock Fund Advisors boosted its stake in shares of Cynosure by 7.1% in the third quarter. BlackRock Fund Advisors now owns 1,722,652 shares of the company’s stock valued at $87,752,000 after buying an additional 114,653 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Cynosure by 2.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,216,198 shares of the company’s stock worth $55,459,000 after buying an additional 28,394 shares during the last quarter. BlackRock Institutional Trust Company N.A. boosted its position in shares of Cynosure by 12.9% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 708,708 shares of the company’s stock worth $36,102,000 after buying an additional 80,700 shares during the last quarter. State Street Corp boosted its position in shares of Cynosure by 4.8% in the fourth quarter. State Street Corp now owns 601,140 shares of the company’s stock worth $27,410,000 after buying an additional 27,748 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its position in shares of Cynosure by 47.6% in the third quarter. Principal Financial Group Inc. now owns 577,910 shares of the company’s stock worth $29,438,000 after buying an additional 186,455 shares during the last quarter.

About Cynosure

Cynosure Inc (Cynosure) develops and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve gynecologic health.

5 Day Chart for NASDAQ:CYNO

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/q1-2017-eps-estimates-for-cynosure-inc-decreased-by-analyst-cyno/1655479.html

Receive News & Ratings for Cynosure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cynosure Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *